Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 349

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 19
Chunk 349
---
 leases its premises in Israel under a lease agreement entered into in August 2014. Payments under the lease commenced in June 2015, and the initial term of the lease expired in June...
────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
In addition to the monthly lease payments, the Company also pays building monthly maintenance charges of approximately $9,000.
The Company leases its premises in Boston under a lease agreement entered into and commencing in October 2022. The lease term will expire in December 2025. The monthly lease fee is approximatel...
────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
The Company has entered into lease agreements in connection with a number of vehicles. The lease periods are generally for three years. The annual lease fees, linked to the CPI, are approximate...
As of December 31, 2024, minimum future rental payments (taking into consideration the aforementioned extension periods) under the leases are as follows:
─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
Year Property
Year Property
───────────────────────────────────────────────────────
in USD thousands
2025 569 146 715
2026 286 61 347
2027 300 13 313
2028-2030 751 - 751
1,906 220 2,126
Extension and termination options are included in most of the property leases. These are used to maximize operational flexibility in terms of managing the assets used in the Company’s operations. The substantial majority of extension and termination options are exercisable solely by the Company and not by the lessors.

F - 31

BioLineRx Ltd.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 - LONG-TERM LOAN

In September 2022, the Company entered into a loan agreement with BlackRock EMEA Venture and Growth Lending (previously Kreos Capital VII Aggregator SCSP) (“ BlackRock”), with an aggregate principal amount of up to $40million comprised of three tranches of up to $10million, $20million and $10million. The Company drew down the initial tranche of $10million following execution of the loan agreement in September 2022 and it drew down the second tranche of $20million in April 2024,